NCT07319728进行中（未招募）1 期
Novel Transdermal Ketoprofen Gel Formulation for Knee Osteoarthritis: Comprehensive In-Vitro and Clinical Assessment
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- McMaster Universities Arthritis Index (WOMAC)
研究概览
简要总结
A single blind randomized controlled clinical study
详细描述
A single blind randomized controlled clinical study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient diagnosed with osteoarthritis in knee by:
- •Full history taking Physical examination including (joint tenderness, swelling, crepitus and limitation of motion).
排除标准
- •1. Patients with dual diagnosis
- •Patients have skin lesion or dermatologic disease in the treatment area
研究组 & 干预措施
formulation arm
Experimental
new formulation of ketoprofen
干预措施: ketoprofen (Drug)
commercial product
Active Comparator
positive control receiving commercial product
干预措施: ketoprofen (Drug)
结局指标
主要结局
McMaster Universities Arthritis Index (WOMAC)
时间窗: 2 weeks
Visual Analogue Scale (VAS)
时间窗: 2 weeks
次要结局
未报告次要终点
研究者
Asmaa Ahmed Hamed Mohie Eldin
Associate professor Clinical pharmacy department
New Valley University
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901Kailera1,156
招募中
2 期
TAR-0520 Gel in taxanes-induced peripheral neuropathy2025-521674-33-00Tarian Pharma30
招募中
3 期
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesObesityNCT07284979Kailera1,200
招募中
3 期
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesObesityNCT07284875Kailera2,340
招募中
3 期
Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary disease called Fragile X Syndrome2024-513888-99-00Harmony Biosciences Management Inc.7